EpiVacCorona, Russia's second COVID-19 vaccine approved after Sputnik V, third on its way
EpiVacCorona, Russia's second COVID-19 vaccine has been approved after Sputnik V/ Sputnik V garnered a lot of criticism from scientists and others around the world.. Russia became the first country to give approval to a COVID-19 vaccine. They registered earlier and started clinical trials on a large scale. President Vladimir Putin announced that the country has registered the second COVID-19 vaccine and a third vaccine is to be released shortly.
He added that vaccines will be first distributed to Russian market on priority. The second vaccine was developed by Vector State Research Centre of Virology and Biotechnology. The two-shot vaccine, 'EpiVacCorona' was tested among 100 volunteers in early-stage. The placebo controlled human trials lasted more than two months and were completed two weeks ago. Volunteers were between 18 and 60 years old.
Vector's vaccine EpiVacCorona relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and absorbed on an aluminium-containing adjuvant. The results are yet to be published. They reported that the vaccines created immunity and antibodies to protect the person who had it from the virus and that the immunity it creates could last for up to six months. 40,000 volunteers have been involved and vaccination is scheduled to start November or December. Deputy Prime Minister of Russia Tatyana Golikova said she tested the vaccine herself and experienced no side effects.
He added that vaccines will be first distributed to Russian market on priority. The second vaccine was developed by Vector State Research Centre of Virology and Biotechnology. The two-shot vaccine, 'EpiVacCorona' was tested among 100 volunteers in early-stage. The placebo controlled human trials lasted more than two months and were completed two weeks ago. Volunteers were between 18 and 60 years old.
Vector's vaccine EpiVacCorona relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and absorbed on an aluminium-containing adjuvant. The results are yet to be published. They reported that the vaccines created immunity and antibodies to protect the person who had it from the virus and that the immunity it creates could last for up to six months. 40,000 volunteers have been involved and vaccination is scheduled to start November or December. Deputy Prime Minister of Russia Tatyana Golikova said she tested the vaccine herself and experienced no side effects.